Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (September 2018)
25 slides from Astrazeneca Pharma India's shareholder meeting presentation, Sep 10, 2018
Slide 1: Welcome to AstraZeneca
Welcome to AstraZeneca Gagan Singh 39th Annual General meeting 10th September 2018
Slide 2: Disclaimer
DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: A global, science-led biopharmaceutical company
A global, science-led biopharmaceutical company Productive R&D • We are focused on innovative science in three therapy areas where we believe that we can make the most meaningful difference to patients. Strong business • We have a stable business of established products and global commercial scale,
Slide 4: The global pipeline forms a robust portfolio of investigational therapies
The global pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. 143 Projects in pipeline 9 new molecular entities in late-stage pipeline New product approvals in 2017 exceed previous 5 years CARDIOVASCULAR, ONCOLOGY RENAL AND RESPIRATORY METABOLISM
Slide 5: Market Overview
Market Overview 5
Slide 6: IPM is poised to grow at ~10% over next four years
Backed by strong demand and macroeconomic factors the ₹ 127,253 Cr IPM is poised to grow at ~10% over next four years Comparison of India’s GDP Growth and IPM growth 20% 18.2% 16.0% 16.3% 14.5% 14.9% 15.3% 16% GROWTH % 10.8% 10.7% 12% 10.2% 9.8% 10.3% 10.1% 8% 5.4% 9.2% 8.5% 8.5% 8.0% 7.4% 7.8% 4% 6
Slide 7: AZPIL
AZPIL 8
Slide 8: AstraZeneca Pharma India Ltd FY 2017-2018
AstraZeneca Pharma India Ltd FY 2017-2018 ₹ 584.24 Cr ₹ 29.95 Cr 1356 Local Manufacturing in Total Revenue1 Clinical trial employees1 India income1 One of the SKU launches in 12% 64% the year Fastest Partner contribution from contribution to growth platforms1 6 growing sales1 major MNCs in IPM* 9 So
Slide 9: 4 decades of bringing science to patients
4 decades of bringing science to patients 2007 2008 Symbicor 2003 BMS Gladis an 2002 R&D partnership Valencia 2001 Zoladex inauguration in India by global Faslodex launched 1998 Merger of launched in AstraZeneca Iressa in India India 1992 Astra IDL crosses Astra & Zeneca to CEO Tom launch 1987 Launc
Slide 10: 4 decades of bringing science to patients
4 decades of bringing science to patients 2018 Xigduo XR 2017 launch 2015 Tagrisso launched 2014 Forxiga launch In India Regulatory approvals: 2012 TPF YHP New SKUs Tagrisso 1L Brilinta Lynparza manufacturing 2011 launch Expansion launched: Symbicort Imfinzi AZPIL 2010 crosses 320/80 , Onglyza & Bri
Slide 11: AZPIL is uniquely positioned to address the unmet need in India
AZPIL is uniquely positioned to address the unmet need in India 43% of all deaths in India are due to Cardiovascular, Diabetes, Respiratory disease and Cancer Share of NCDs in mortality in India % 169 m hypertensive patients % of total deaths, all ages 30% 26% 65 m diabetics patients (Will become ~
Slide 12: Committed to impacting patient lives with upcoming launches
Committed to impacting patient lives with upcoming launches* ONCOLOGY CARDIOVASCULAR RENAL AND RESPIRATORY METABOLIC DISEASE Late stage pipeline and key lifecycle medicines Bevespi Tagrisso Xigduo XR COPD Lung cancer diabetes Fasenra Imfinzi TREAT Severe uncontrolled asthma Lung cancer, Bladder canc
Slide 13: AstraZeneca ranks 8th and is amongst the fastest growing MNCs in IPM
AstraZeneca ranks 8th and is amongst the fastest growing MNCs in IPM1 In market Rank Company MS% GR% Val (Cr) Brilinta in Top 100 IPM 123762 100 7.8 Products of IPM2 1 Abbott 7791 6.30 11.1 2 Glaxo 3666 2.96 8.0 3 Pfizer 2948 2.38 -1.8 4 Sanofi India 2736 2.21 6.4 5 Novartis 1371 1.11 5.4 Forxiga in
Slide 14: Reaching out to more patients in Oral Antiplatelet market
Reaching out to more patients in Oral Antiplatelet market TICAGRELOR is the fastest growing OAP, molecule Innovative Initiatives helping us to achieve key reaching 32% MS** internal Milestones 60% > Compliance Pack helping to address adherence ,Accessibility 50% & affordability to activate Duration
Slide 15: Dapagliflozin franchise on a high growth trajectory
Dapagliflozin franchise on a high growth trajectory More than 25k patients since launch Exceeded previous benchmarks of Fixed dose combination launches in innovative OAD space 16 Source: *IMS MAT July 2018
Slide 16: Tagrisso has touched >260 patient lives since launch
Tagrisso has touched >260 patient lives touched since launch ; Gearing up to benefit more patients with 1L indication Levers that played a role A strong pre-launch Focus on Scientific knowledge exchange with achievement reimbursed and laboratory capability Of 100% of pre- channels building drives up
Slide 17: Addressing events impacting IPM
Addressing events impacting IPM EVENTS AZPIL INITIATIVES GST AZPIL was well prepared ahead of GST implementation Uniform Code for Pharmaceuticals Company has already implemented the same and is well Marketing Practices positioned for roll out of code AZPIL has a greater dependency on patented produc
Slide 18: Committed to fighting NCDs
Committed to fighting NCDs 19
Slide 19: AZ to be the Trusted Partner of GoI in the fight against NCDs
AZ to bewe’re What the Trusted Partner of GoI in the fight against NCDs doing…. Nov’17: Dec’ 17 Meeting with Maharashtra CM at Meeting with CEO, Niti Aayog Make in India, Sweden Young Health Programme We’re commonmaking NCDs, targetingour science Program which focuses on primary prevention risk beha
Slide 20: AZ as a trusted partner in providing innovative healthcare delivery solutions
AZ as a trusted partner in providing innovative healthcare delivery solutions EARLY ACTION IN DIABETES MoU with the Department of Health & Family Welfare Kerala to o set up a 360 Centre of Excellence for Management of Diabetes and associated metabolic diseases at Government General Hospital, Ernakul
Slide 21: Community service
Community service
Slide 22: Making a meaningful difference to the community
Making a meaningful difference to the community COMMUNITY DAY – MARCH 2018 • Over 10,000 people reached in 4 urban slum communities • 923 screened for diabetes, hypertension and respiratory diseases
Slide 23: One AstraZeneca Week - August 2018
One AstraZeneca Week - August 2018 National Community Service Program Focus on prevention of NCDs and young people Impact 3,000+ young people in a nation- wide NCD Sensitation in schools and community outreach programme
Slide 24: Summary
Summary 1. Growing healthcare and pharma market is fueling the company’s growth 2. AstraZeneca’s portfolio is well-positioned to address India’s growing disease burden in NCDs 3. We expect to impact ~3 million patients in India through our life-changing medicines 4. AstraZeneca continues to outperfo
Slide 25: Making a difference by touching lives of patients
Making a difference by touching lives of patients 26
AstraZeneca Pharma India — Shareholder Meeting (September 2018) on 6ix